Pharmacy Grand Rounds
To Be or Not to Be: Benefits and Challenges of 340B

• ACPE Universal Activity Number (UAN): JA0000238-0000-21-004-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until further notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION
Since its establishment in 1992, the 340B program has been affording hospitals and clinics throughout the country with price discounts to expand access of care to the most vulnerable patients. Challenged by operational and regulatory requirements, the 340B program has recently come under scrutiny. In addition to a review of current state, we will also explore recent concerns raised with regard to this program and consider what the potential consequences might be if significant changes were to occur.

LEARNING OBJECTIVES
At the conclusion of this knowledge-based CE session, participants should be able to:

• Identify the purpose of 340B and the impact on health care costs
• Evaluate the role of 340B contract pharmacies
• Review challenges facing the 340B program and potential consequences

Session Announcement.pdf

340B PGR.pdf

FACULTY INFORMATION

Dylan L. Kosaski, Pharm.D.
PGY-2 Health System Pharmacy Administration Resident
Mayo Clinic Hospital - Rochester, MN

Dylan received a Doctor of Pharmacy degree from Ferris State University in Grand Rapids, MI. He is currently a second-year Health System Pharmacy Administration residency at Mayo Clinic – Rochester. As a part of his residency training he is also completing the American Society of Health-System Pharmacists Pharmacy Leadership Academy where he is able to explore the challenges facing pharmacy through collaboration with leaders around the country.  

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Dylan L. Kosaski, PharmD
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. 

Members include:

• Jennifer Elmer, DNP, APRM, CCNS, FCCM
• Michael Huckabee, MPAS, PA-C, PhD
• Sarah Jane Kotval
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS
• Brenda Stellmaker